These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 30790732)

  • 21. CDC25B, Ki-67, and p53 expressions in reactive gliosis and astrocytomas.
    Suren D; Isiksacan Ozen O
    J BUON; 2013; 18(4):1006-11. PubMed ID: 24344030
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
    Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
    Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicenter imaging outcomes study of The Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival.
    Wangaryattawanich P; Hatami M; Wang J; Thomas G; Flanders A; Kirby J; Wintermark M; Huang ES; Bakhtiari AS; Luedi MM; Hashmi SS; Rubin DL; Chen JY; Hwang SN; Freymann J; Holder CA; Zinn PO; Colen RR
    Neuro Oncol; 2015 Nov; 17(11):1525-37. PubMed ID: 26203066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cut-point for Ki-67 proliferation index as a prognostic marker for glioblastoma.
    Wong E; Nahar N; Hau E; Varikatt W; Gebski V; Ng T; Jayamohan J; Sundaresan P
    Asia Pac J Clin Oncol; 2019 Feb; 15(1):5-9. PubMed ID: 29336530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Value of ALDH1, EZH2 and Ki-67 in Astrocytic Gliomas.
    Ahmed S; Rashed H; Hegazy A; Mohamed AM; Elmesallamy W
    Turk Patoloji Derg; 2016; 32(2):70-81. PubMed ID: 27136105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.
    Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH
    J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma.
    Wolfsberger S; Fischer I; Höftberger R; Birner P; Slavc I; Dieckmann K; Czech T; Budka H; Hainfellner J
    Am J Surg Pathol; 2004 Jul; 28(7):914-20. PubMed ID: 15223962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of Multifocality and Molecular Markers on Survival of Glioblastoma.
    Ahmadipour Y; Jabbarli R; Gembruch O; Pierscianek D; Darkwah Oppong M; Dammann P; Wrede K; Özkan N; Müller O; Sure U; El Hindy N
    World Neurosurg; 2019 Feb; 122():e461-e466. PubMed ID: 30347300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of 10 different polymorphisms on preoperative volumetric characteristics of glioblastoma multiforme.
    Henker C; Kriesen T; Fürst K; Goody D; Glass Ä; Pützer BM; Piek J
    J Neurooncol; 2016 Feb; 126(3):585-92. PubMed ID: 26603163
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of subventricular zone involvement in relation to tumor volumes defined by fused MRI and O-(2-[
    Harat M; Małkowski B; Roszkowski K
    Radiat Oncol; 2019 Mar; 14(1):37. PubMed ID: 30832691
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature.
    Reavey-Cantwell JF; Haroun RI; Zahurak M; Clatterbuck RE; Parker RJ; Mehta R; Fruehauf JP; Brem H
    J Neurooncol; 2001 Dec; 55(3):195-204. PubMed ID: 11859975
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.
    Kickingereder P; Wiestler B; Burth S; Wick A; Nowosielski M; Heiland S; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2015 Aug; 17(8):1139-47. PubMed ID: 25754089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation of diffusion tensor, dynamic susceptibility contrast MRI and (99m)Tc-Tetrofosmin brain SPECT with tumour grade and Ki-67 immunohistochemistry in glioma.
    Alexiou GA; Zikou A; Tsiouris S; Goussia A; Kosta P; Papadopoulos A; Voulgaris S; Kyritsis AP; Fotopoulos AD; Argyropoulou MI
    Clin Neurol Neurosurg; 2014 Jan; 116():41-5. PubMed ID: 24309151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determining a cut-off residual tumor volume threshold for patients with newly diagnosed glioblastoma treated with temozolomide chemoradiotherapy: A multicenter cohort study.
    Woo PYM; Ho JMK; Tse TPK; Lam SW; Mak CHK; Chan DTM; Lee MWY; Wong ST; Chan KY; Poon WS
    J Clin Neurosci; 2019 May; 63():134-141. PubMed ID: 30712777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Threshold of the extent of resection for WHO Grade III gliomas: retrospective volumetric analysis of 122 cases using intraoperative MRI.
    Fujii Y; Muragaki Y; Maruyama T; Nitta M; Saito T; Ikuta S; Iseki H; Hongo K; Kawamata T
    J Neurosurg; 2018 Jul; 129(1):1-9. PubMed ID: 28885120
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Imaging Biomarkers in Glioblastoma: Development and Independent Validation on the Basis of Multiregion and Quantitative Analysis of MR Images.
    Cui Y; Tha KK; Terasaka S; Yamaguchi S; Wang J; Kudo K; Xing L; Shirato H; Li R
    Radiology; 2016 Feb; 278(2):546-53. PubMed ID: 26348233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dynamics of FLAIR Volume Changes in Glioblastoma and Prediction of Survival.
    Grossman R; Shimony N; Shir D; Gonen T; Sitt R; Kimchi TJ; Harosh CB; Ram Z
    Ann Surg Oncol; 2017 Mar; 24(3):794-800. PubMed ID: 27766560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
    Schmainda KM; Zhang Z; Prah M; Snyder BS; Gilbert MR; Sorensen AG; Barboriak DP; Boxerman JL
    Neuro Oncol; 2015 Aug; 17(8):1148-56. PubMed ID: 25646027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Classification of microvascular patterns via cluster analysis reveals their prognostic significance in glioblastoma.
    Chen L; Lin ZX; Lin GS; Zhou CF; Chen YP; Wang XF; Zheng ZQ
    Hum Pathol; 2015 Jan; 46(1):120-8. PubMed ID: 25455996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.